Last updated on January 2020

Study Of Nivolumab Alone Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma


Brief description of study

This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses. :

  • In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based response), patients will receive 18 additional cycles of Nivolumab, according to CT-based response at Cycle 12.
  • In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive 12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at Cycle 12.
  • In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure.

Clinical Study Identifier: NCT03580408

Find a site near you

Start Over

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

Az Sint Jan

Bruges, Belgium
  Connect »

Hopital Jolimont

Haine saint paul, Belgium
  Connect »

Az Groeninge

Kortrijk, Belgium
  Connect »

CHU de Clermont Ferrand

Clermont Ferrand, France
  Connect »

CHD de Vend e

La Roche-sur-Yon, France
  Connect »

CH La Rochelle

La Rochelle, France
  Connect »

CH du Mans

Le Mans, France
  Connect »

Centre Leon Berard

Lyon Cedex 8, France
  Connect »

CHU Lyon Sud

Pierre-Bénite, France
  Connect »

Ch Rene Dubos

Pontoise, France
  Connect »

CH de Saint Brieuc

Saint-Brieuc, France
  Connect »

IUCT Toulouse

Toulouse, France
  Connect »

CHU Brabois

Vandoeuvre les Nancy, France
  Connect »

Institut Gustave Roussy

VILLEJUIF Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.